Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
WEBIn an interview, Jaime Merchan, MD, explained the background and data from a biomarker analysis of the CLEAR trial in advanced renal cell carcinoma. Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Daratumumab With VRd Induced VGPR in 100% of ... - Targeted …
WEBDec 3, 2018 · Peter Voorhees, MD. In a study of transplant-eligible patients with newly diagnosed multiple myeloma (MM), daratumumab (Darzalex) added to bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) induced at least a very good partial response (VGPR) in all patients, including a stringent complete response (sCR) or CR in 63% of ...
Using Capecitabine/Temozolomide or 177Lu-Dotatate to Treat …
WEBFeb 1, 2022 · The regimen typically consists of capecitabine 750 mg/m 2 twice daily on days 1 to 14 and temozolomide 200 mg/m² once daily (typically at bedtime) on days 10 to 14 every 28 days (FIGURE 1). In practice, doses usually are rounded down to minimize the use of different pills. Thus, actual starting doses are often slightly lower than target doses ...
Addressing the Presence of NTRK Gene Fusions in Thyroid Cancer
WEBJul 12, 2022 · NTRK gene fusions are key molecular markers in thyroid cancer. Knowledge of the presence of NTRK gene fusions in patients with thyroid cancer can help with diagnosis, determining prognosis, and selecting the optimal treatment plan for the patient. 1. Since 2019, the FDA has granted approval to 2 agents for the treatment TRK fusion-positive cancer. First, larotrectinib (Vitrakvi) was approved ...
Managing Chemotherapy Toxicities for Improved Patient Outcomes
WEBMar 29, 2021 · In a large majority of patients, even when treating with chemotherapy that is highly emetogenic, nausea and vomiting can be prevented. Options include 5-HT3 receptor antagonists (such as ondansetron), NK-1 receptor antagonists (such as aprepitant), glucocorticoids (such as dexamethasone), and olanzapine, a …
TAS-102 Receives FDA Approval for Gastric/GEJ Cancer
WEBFeb 25, 2019 · Patients were randomized 2:1 to receive TAS-102 (35 mg/m 2 twice daily on days 1 to 5 and 8 to 12 of each 28-day cycle) or placebo plus best supportive care, and were treated until progression, intolerability, or patient withdrawal. The primary cancer site was gastric in 71% and GEJ in 29%. Fifty-five percent had ≥3 metastatic sites.
Recent Approvals Signal a Bright Future for Myelodysplastic …
WEBDec 22, 2023 · Ivosidenib . In October 2023, ivosidenib (Tibsovo) was cleared by the FDA for the treatment of IDH1-mutated relapsed or refractory MDS, based on findings from the AG120-C-001 trial (NCT02074839).4 In the study, 18 adult patients with relapsed or refractory MDS with an IDH1 mutation received oral ivosidenib daily on a 28-day cycle. All responses in the trial were complete responses (CRs), and ...
FDA Grants Breakthrough Designation to Zanidatamab for HER2 …
WEBNov 30, 2020 · The FDA has granted a Breakthrough Therapy designation to zanidatamab (formerly ZW25) as treatment of patients with previously treated HER2-amplified biliary tract cancer, announced Zymeworks Inc. in a press release. This designation is supported by an ongoing phase 2b clinical trial (NCT04466891) of this agent as treatment of patients with ...
FDA Allows Magrolimab Studies to Continue in Patients With MDS …
WEBApr 12, 2022 · The FDA has lifted the partial clinical hold placed on studies of magrolimab in combination with azacitidine (Vidaza). Comprehensive safety data were reviewed by the FDA from all studies, leading the regulatory body to their decision. 1 Uncertain data around the investigator-reported serious adverse reaction between treatment arms was the reason for the partial clinical hold placed in January ...
Genetic Testing Informs Treatment Decisions in Melanoma
WEBMay 14, 2021 · Douglas B. Johnson, MD, MSCI. Novel methods of genetic testing have led to improved detection and better clinical decisions in patients with melanoma, especially in the late-stage setting. However, with multiple tests available, determining when to order a test, which test to order, and exactly how to integrate other immunohistochemistry (IHC ...